Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
NCT ID: NCT00804934
Last Updated: 2012-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2008-02-29
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
NCT01269151
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01940900
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
NCT00590694
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
NCT01255774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0
Lucentis
0.5mg Lucentis every four months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lucentis
0.5mg Lucentis every four months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater then and equal 50 years
* Patients with active neovascular AMD
* Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
* If the patient has bilateral disease and qualifies for the study, both eyes may be included
Exclusion Criteria
* Pregnancy or lactation
* Premenopausal women not using adequate contraception.
* Participation in another simultaneous medical investigation
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Retina Institute of Hawaii
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Debra L Shimabukuro, RN
Role: STUDY_CHAIR
Retina Institute of Hawaii
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Institute of Hawaii
Honolulu, Hawaii, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F4421S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.